Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences

Author's Avatar
Feb 11, 2021
Article's Main Image

Humanigen%2C+Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s CEO, Cameron Durrant, will participate, present and host meetings with investors and industry colleagues at the BIO CEO & Investor Virtual Conference and the Endpoints Webinars panel, “Repurposing drugs for new indications: benefits and challenges,” and will co-host the Vanguard Network Life Sciences Quarterly Forum. Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.